e-Profile Login and ID Quick Search
NABP e-News: April 02, 2009
Technician Education Task Force and LE/L Committee Reports Posted
The NABP Executive Committee has reviewed the recommendations of the following 2008-2009 task force and committee. The reports are posted under News/Press on the NABP Web site.
- Task Force on Standardized Pharmacy Technician Education and Training
- Committee on Law Enforcement/Legislation
GAO Issues Report on Proposed Behind-the-Counter Class of Drugs
The United States Government Accountability Office (GAO) recently released a report on the proposed establishment of a behind-the-counter (BTC) class of drugs (GAO-09-245). The report addresses arguments supporting and opposing a BTC drug class, changes in drug availability in five countries since 1995 and the impact of restricted nonprescription classes on availability, as well as issues important to the establishment of a BTC drug class. The report, “Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class,” is available on the GAO Web site.
HHS Proposes to Rescind Bush’s 11th Hour Conscience Clause
The Department of Health and Human Services (HHS) has issued a proposal to rescind the December 19, 2008 final rule to strengthen health care workers’ right of conscience. The rule, entitled “Ensuring That Department of Health and Human Services Funds Do Not Support Coercive or Discriminatory Policies or Practices in Violation of Federal Law,” was promulgated by HHS during President Bush's last days in office. The rule met with a flurry of legislative and legal activity by opponents eager to repeal the move, as well as support from proponents who want to protect it. The proposal to rescind the rule was published in the March 10, 2009 Federal Register. HHS will accept comments on the regulatory changes proposed by this document through April 9, 2009.
FDA Posts Questions and Answers about Initiative Against Contaminated Weight Loss Products
Food and Drug Administration (FDA) has posted on its Web site a series of questions and answers to help patients, health care practitioners, and the general public to understand FDA’s actions regarding weight loss products contaminated with various prescription drugs and chemicals. The information includes a list of the weight loss products associated with this action, the undeclared drugs and/or chemicals contained in these products, risks associated with these chemicals, and FDA’s actions in regard to this initiative.
